Compare WWR & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WWR | NSPR |
|---|---|---|
| Founded | 1977 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.3M | 72.1M |
| IPO Year | 2006 | 2009 |
| Metric | WWR | NSPR |
|---|---|---|
| Price | $0.51 | $0.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.92 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 936.5K | 164.0K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.47 | $0.69 |
| 52 Week High | $3.75 | $2.93 |
| Indicator | WWR | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 30.58 |
| Support Level | $0.47 | N/A |
| Resistance Level | $0.72 | $1.04 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 28.58 | 9.15 |
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.